Experimental Drug Targeting Calcium Channels May Interrupt Immune Dysfunction in Severe Pneumonia
Source Summary
A new study published in The Journal of Clinical Investigation shows that Auxora, an experimental drug that blocks CRAC channels, may help interrupt harmful immune cell interactions that drive severe viral pneumonia. The findings provide insight into how the drug works and may inform future precision medicine approaches to treating pneumonia, according to the study's senior author, G. R. Scott Budinger, MD.
Why it matters
Understanding how Auxora interrupts harmful immune responses in severe pneumonia may enable development of more targeted treatments for a serious respiratory condition.
